Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Time to treat the climate and nature crisis as one indivisible global health emergency
Expert Rev Pharmacoecon Outcomes Res. 2023 Oct 30:1-3. doi: 10.1080/14737167.2023.2276519. Online ahead of print.NO ABSTRACTPMID:37902060 | DOI:10.1080/14737167.2023.2276519 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 30, 2023 Category: Health Management Authors: Kamran Abbasi Parveen Ali Virginia Barbour Thomas Benfield Kirsten Bibbins-Domingo Gregory E Erhabor Stephen Hancocks Richard Horton Laurie Laybourn-Langton Robert Mash Peush Sahni Wadeia Mohammad Sharief Paul Yonga Chris Zielinski Source Type: research

Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals
Expert Rev Pharmacoecon Outcomes Res. 2023 Oct 30:1-6. doi: 10.1080/14737167.2023.2275674. Online ahead of print.ABSTRACTINTRODUCTION: The 21st century has brought about significant technological advancement, allowing the collection of new types of data from the real world on an unprecedented scale. The healthcare industry will benefit immensely from this abundance of patient data from electronic health records (EHR), patient-reported outcomes (PROs), laboratory, demographic, social media, digital, and even climate data.AREAS COVERED: While conventional statistical methods still play a significant role in supporting the dr...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 30, 2023 Category: Health Management Authors: Won Chan Lee Source Type: research

Payer and Developer perspectives on alternative payment models
CONCLUSION: Although limited by the number of participants, this survey indicates early discussions coupled with understanding motivations are essential for developing contracts that appeal to both parties and ensure patient access.PMID:37883069 | DOI:10.1080/14737167.2023.2276374 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 26, 2023 Category: Health Management Authors: Renita Moradian Tsega Meshesha Mark Trusheim Jane F Barlow Source Type: research

Natural language processing - relevance to patient outcomes and real-world evidence
Expert Rev Pharmacoecon Outcomes Res. 2023 Oct 24. doi: 10.1080/14737167.2023.2275670. Online ahead of print.NO ABSTRACTPMID:37874661 | DOI:10.1080/14737167.2023.2275670 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 24, 2023 Category: Health Management Authors: Robert Stewart Jaya Chaturvedi Angus Roberts Source Type: research

Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review
Expert Rev Pharmacoecon Outcomes Res. 2023 Oct 20:1-12. doi: 10.1080/14737167.2023.2266135. Online ahead of print.ABSTRACTINTRODUCTION: We aimed to summarize evidence on the effect of poor medication adherence on clinical outcomes and health resource utilization (HRU) among patients with hypertension and/or dyslipidemia.AREAS COVERED: A systematic review of studies reporting clinical outcomes and HRU for patients by status of adherence to antihypertensives and/or lipid-lowering medications was searched using Embase, MEDLINE, and MEDLINE In-Process and supplemented by manual searches of conference abstracts. In total, 45 st...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 20, 2023 Category: Health Management Authors: Andr é Pascal Kengne Jean-Baptiste Bri ère Luc ía Zhu Jingya Li Mandeep Kaur Bhatia Petar Atanasov Zeba M Khan Source Type: research

Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China
CONCLUSIONS: Toripalimab plus chemotherapy was likely to be the cost-effective first-line option for patients with advanced ESCC compared with chemotherapy alone with the WTP threshold of $38,224 per additional QALY gained from the perspective of the Chinese health-care system.PMID:37855081 | DOI:10.1080/14737167.2023.2270159 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 19, 2023 Category: Health Management Authors: Shuo Kang Xiaohui Wang Zhenhua Pan Huanlong Liu Source Type: research